Abstract

The DAB CFAR Developmental Core has made a significant impact on HIV/AIDS research programs since the inception of the Center in 1988. The primary tool of the Developmental Core is the Developmental Grant Program which funds peer reviewed intramural HIV/AIDS related research grants targeted to junior faculty members and investigators new to the HIV/AIDS field. Since the inception of this program, a total of $2.069.115 were used to competitively fund 87 Developmental grants, selected from a total of 235 applications submitted to the UAB CFAR Developmental Grant Program. This investment has yielded $65.537.542 in extramural grant direct cost funding for a return on investment of $31 for every $1 of Developmental Grant Program money. This value has been maintained over the last funding period with $20 per every 1 of CFAR Developmental grant money. Embedded in the Developmental Grant Program is the core's mentoring program. Applicants are provided an experienced mentor from the CFAR Executive Board or CFAR Core Director in a related research area to the proposed project.
The Specific Aims of the Developmental core are:
Specific Aim 1. Specific Aim 2. To continue to administer the highly successful CFAR Developmental Grant Program. The Developmental Core will continue to fund 4 high quality proposals each year. A mentoring program will be provided to each of the awardees. The Core will also facilitate development of IRGs designed to bring new HIV/AIDS research to the CFAR. To provide faculty development resources to HIV/AIDS investigators. The Developmental Core will provide services to facilitate grant submission and review. The Core will also implement new educational opportunities to graduate students and fellows to become familiar with HIV/AIDS research. The Developmental Core will continue to play an integral part in the continued vitality of the HIV/AIDS research endeavor. During the next funding period, several innovative, new programs will be developed to support CFAR interdisciplinary research groups (IRG) and individual UAB CFAR investigators.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-25
Application #
8495864
Study Section
Special Emphasis Panel (ZAI1-SV-A)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$2,913,655
Indirect Cost
$205,184

  Institution

Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Stafman, Laura L; Mruthyunjayappa, Smitha; Waters, Alicia M et al. (2018) Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget 9:22665-22679
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372

Showing the most recent 10 out of 955 publications